Abstract

Aim: Multiple myeloma (MM) is a malignant plasma cell disorder. Prognosis varies according to several factors, including laboratory parameters, comorbidities, and treatment strategies. The aim of this study was to evaluate prognostic markers and survival outcomes in patients with MM.
Materials and Methods: A retrospective study was conducted on 180 patients diagnosed with MM at Mersin University Hospital between 2005 and 2017. Demographic, clinical, laboratory, and treatment data were collected at diagnosis. Patients were staged according to the International Staging System (ISS) and the Durie–Salmon classification. Prognostic and mortality analyses included demographic characteristics, laboratory parameters (e.g., hemoglobin, renal function, calcium, platelet count), disease stage, and treatment modalities.
Results: Median overall survival (OS) was significantly longer in patients under 65 years of age compared to those aged 65 years and older (41.3 vs. 20.7 months, p

Key words: Multiple myeloma, prognostic factors, survival analysis